FIG. 1



Melanomas (uveal)
Thymic cancers
Sarcomas (peritoneal, retroperitoneal)
Gastrointestinal stromal tumors
Thyroid cancers
Lung cancers (small-cell)
Kidney cancers
Glioblastoma multiforme, high grade gliomas
Neuroendocrine tumors
Sarcomas (soft tissues)
Melanoma
Ovarian (non-epithelial) cancers
Hepatocellular carcinomas
Prostate cancers
Cholangiocarcinomas (intrahepatic)
Pancreatic adenocarcinomas
Intestinal (small) malignancies
Lung cancers (non-small cells)
Head and neck carcinomas
Ovarian (epithelial) cancers
Colorectal cancers
Unknown primary cancers
Uterine cancers
Uterine and cervical cancers
Cervical cancers
Gastric adenocarcinomas
Cholangiocarcinomas (extrahepatic)
Gallbladder cancers
Breast cancers
Esophageal, esophagogastric junction cancers
Bladder cancers
Trastuzumab (Herceptin) Investigational Sponsored Trials
Anti-HER2 therapies Approved (US, International)
0%
2%
4%
6%
8%
10%
12%
14%

FIG. 2A



OS
HER2 amplified 15.5 months
Non-amplified 29.7 months
Proportion surviving
0
.2
.4
.6
.8
1
0
10
20
30
40
50
60
70
80
Time (months)

FIG. 2B





PFS
HER2 amplified 10 months
Non-amplified 14.1 months
Proportion surviving
0
.2
.4
.6
.8
1
0
10
20
30
40
50
60
70
80
Time (months)

FIG. 3A



%TGI on study Day 29:
Tucatinib 104%
Trastuzumab 109%
Tucatinib + Trastuzumab 124%

FIG. 3B



%TGI on study Day 29:
Tucatinib 50%
Trastuzumab 36%
Tucatinib + Trastuzumab 103%

FIG. 3C




Efficacy of Tucatinib and Trastuzumab
in CRC PDX CTG-0383
Group Mean Tumor Volume
Tumor Volume (mm3)
800
600
400
200
0
0
7
14
21
28
Study Day
Vehicle Control
Tucatinib
Trastuzumab
Tucatinib + Trastuzumab
Group Mean +/- SEM
n=10/group

FIG. 4A



%TGI on study Day 15:
Tucatinib 49%
Trastuzumab 55%
Tucatinib + Trastuzumab 85%

FIG. 4B




FIG. 5A



Effiect on Tumor Growth of Tucatinib and Trastuzumab
in Gastric Cancer PDX GXA 3038
Group Mean (n=10) Tumor Volume ± SD
Tumor Volume (mm3)
1000
800
600
400
200
0
0
7
14
21
28
Study Day
Vehicle Control
Tucatinib: 50 mg/kg/dose, PO, BID x 28
Trastuzumab: 20 mg/kg/dose, IP, Q3D x 9
Tucatinib + Trastuzumab

FIG. 5B



Effect on Tumor Growth of Tucatinib and Trastuzumab
in Gastric Cancer PDX GXA 3039
Group Mean (n=7) Tumor Volume ± SD
Tumor Volume (mm3)
2000
1500
1000
500
0
0
7
14
21
28
35
Study day
Vehicle Control
Tucatinib: 50 mg/kg/dose, PO, BID x 28
Trastuzumab: 20 mg/kg/dose, IP, Q3D x 9
Tucatinib + Trastuzumab

FIG. 5C



Anti-Tumor Effect of Tucatinib and Trastuzumab
in Gastric Cancer PDX GXA 3054
Group Mean (n=10) Tumor Volume ± SD
Tumor Volume (mm3)
500
400
300
200
100
0
0
7
14
21
28
Study Day
Vehicle Control
Tucatinib: 50 mg/kg/dose, PO, BID x 28
Trastuzumab: 20 mg/kg/dose, IP, Q3D x 9
Tucatinib + Trastuzumab

FIG. 6



Efficacy of Tucatinib and Trastuzumab
in Cholangiocarcinoma PDX CTG-0927
Group Mean Tumor Volume
Tumor Volume (mm3)
2000
1500
1000
500
0
0
7
14
21
28
35
Study Day
Vehicle Control
Tucatinib
Trastuzumab
Tucatinib + Trastuzumab
Group Mean +/- SEM
n=10/group

FIG. 7A





FIG. 7B



% TGI on study day 39
Tucatinib 80%
Trastuzumab 61%
Tucatinib + trastuzumab 98%